| Description |
1 online resource (114 pages) |
| Contents |
Cover; Contents; Title page; Copyright; Preface; Chapter 1: Epidemiology and Pathogenesis of Type 2 Diabetes; The current prevalence of diabetes; Factors driving the type 2 diabetes epidemic; Pathogenesis of type 2 diabetes; References; Chapter 2: Overview of Current Diabetes Management; Recommended targets for glycaemic control; Pros and cons of existing non-insulin antidiabetes therapies; Why are new drugs needed for the treatment of type 2 diabetes?; References; Chapter 3: The Incretin System; References; Chapter 4: The Incretin Mimetics; Exenatide; Liraglutide |
|
Place in therapy of the incretin mimeticsReferences; Chapter 5: Dipeptidyl Peptidase-4 Inhibitors; Mechanism of action; DPP-4 inhibitor clinical efficacy; Vildagliptin; Saxagliptin; DPP-4 inhibitor safety and tolerability; DPP-4 inhibitor advantages and disadvantages; DPP-4 inhibitor current indications; Place in therapy of the DPP-4 inhibitors; References; Chapter 6: Sodium-glucose Cotransporter-2 Inhibitors; Dapagliflozin; Safety and tolerability; SGLT-2 inhibitor advantages and disadvantages; References; Chapter 7: Pipeline Diabetes Therapies; Taspoglutide; Linagliptin |
|
Bile acid receptor agonistsGlucokinase activators; Sirtuins; Sodium-glucose cotransporter-1 inhibitors; Sodium-glucose cotransporter-2 antisense inhibitors; Glucose-dependent insulinotropic polypeptide agonists and antagonists; Glucagon receptor antagonists; References; Chapter 8: Bariatric Surgery for the Treatment of Type 2 Diabetes; Potential mechanisms of diabetes resolution after bariatric surgery; Efficacy of bariatric surgery for the treatment of type 2 diabetes; Considerations; References; Chapter 9: Organization of Diabetes Care; Managing diabetes in primary care |
|
Delivery of diabetes care closer to homeStructured patient education programmes; References; Index |
| Summary |
New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabete |
| Notes |
Print version record |
| Subject |
Type 2 diabetes
|
|
Hypoglycemic agents.
|
|
Obesity -- Surgery.
|
|
Diabetes Mellitus, Type 2
|
|
Hypoglycemic Agents
|
|
Hypoglycemic agents
|
|
Type 2 diabetes
|
|
Obesity -- Surgery
|
| Form |
Electronic book
|
| Author |
Grice, Jenny
|
| ISBN |
9781118682203 |
|
1118682203 |
|
